ESPR (Esperion Therapeutics, Inc.)
Insider Trading Activity
Every open-market purchase and sale reported by ESPR officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-07-13 | John B. Harlow Jr. | Chief Commercial Officer | D | — | — |
| 2026-07-13 | J MARTIN CARROLL | Director | D | — | — |
| 2026-07-13 | Benjamin Looker | Chief Legal Officer | D | — | — |
| 2026-07-13 | Jay Shepard | Director | D | — | — |
| 2026-07-13 | Benjamin Halladay | Chief Financial Officer | D | — | — |
| 2026-07-13 | Robert E. Hoffman | Director | D | — | — |
| 2026-07-13 | Sheldon L. Koenig | President and CEO | D | — | — |
| 2026-07-13 | Seth H. Z. Fischer | Director | D | — | — |
| 2026-07-13 | JOHN CRAIG THOMPSON | Director | D | — | — |
| 2026-06-18 | Sheldon L. Koenig | President and CEO | Sell | — | — |
| 2026-06-18 | Benjamin Halladay | Chief Financial Officer | Sell | — | — |
| 2026-06-18 | Benjamin Looker | Chief Legal Officer | Sell | — | — |
| 2026-06-01 | J MARTIN CARROLL | Director | A | — | — |
| 2026-06-01 | Robert E. Hoffman | Director | A | — | — |
| 2026-06-01 | JOHN CRAIG THOMPSON | Director | A | — | — |
| 2026-06-01 | Seth H. Z. Fischer | Director | A | — | — |
| 2026-06-01 | Jay Shepard | Director | A | — | — |
| 2026-03-18 | Sheldon L. Koenig | President and CEO | Sell | — | — |
| 2026-03-18 | Benjamin Halladay | Chief Financial Officer | Sell | — | — |
| 2026-03-18 | Benjamin Looker | Chief Legal Officer | Sell | — | — |
| 2026-03-16 | Benjamin Looker | Chief Legal Officer | A | — | — |
| 2026-03-16 | Sheldon L. Koenig | President and CEO | A | — | — |
| 2026-03-16 | Benjamin Halladay | Chief Financial Officer | A | — | — |
| 2026-01-21 | Benjamin Looker | General Counsel | Sell | — | — |
| 2025-12-18 | Benjamin Halladay | Chief Financial Officer | Sell | — | — |
| 2025-12-18 | Benjamin Looker | General Counsel | Sell | — | — |
| 2025-12-18 | Sheldon L. Koenig | President and CEO | Sell | — | — |
| 2025-12-08 | John B. Harlow Jr. | Chief Commercial Officer | A | — | — |
| 2025-10-20 | Benjamin Looker | General Counsel | Sell | — | — |
| 2025-09-18 | Benjamin Looker | General Counsel | Sell | — | — |
| 2025-09-18 | Sheldon L. Koenig | President and CEO | Sell | — | — |
| 2025-09-18 | Benjamin Halladay | Chief Financial Officer | Sell | — | — |
| 2025-07-18 | Benjamin Halladay | Chief Financial Officer | Sell | — | — |
| 2025-07-18 | Benjamin Looker | General Counsel | Sell | — | — |
| 2025-07-02 | JOHN CRAIG THOMPSON | Director | A | — | — |
| 2025-06-18 | Benjamin Halladay | Chief Financial Officer | Sell | — | — |
| 2025-06-18 | Benjamin Looker | General Counsel | Sell | — | — |
| 2025-06-18 | Sheldon L. Koenig | President and CEO | Sell | — | — |
| 2025-06-02 | NICOLE VITULLO | Director | A | — | — |
| 2025-06-02 | Robert E. Hoffman | Director | A | — | — |
| 2025-06-02 | J MARTIN CARROLL | Director | A | — | — |
| 2025-06-02 | Jay Shepard | Director | A | — | — |
| 2025-06-02 | Tracy M Woody | Director | A | — | — |
| 2025-06-02 | STEPHEN ROCAMBOLI | Director | A | — | — |
| 2025-06-02 | Seth H. Z. Fischer | Director | A | — | — |
| 2025-04-21 | Benjamin Halladay | Chief Financial Officer | Sell | — | — |
| 2025-04-21 | Eric Warren | Chief Commercial Officer | Sell | — | — |
| 2025-04-02 | Robert E. Hoffman | Director | A | — | — |
| 2025-03-19 | Benjamin Halladay | Chief Financial Officer | Sell | — | — |
| 2025-03-19 | Eric Warren | Chief Commercial Officer | Sell | — | — |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| — | 10%+ Owner | 4,477,964 | — |
| — | 10%+ Owner | 3,652,964 | — |
| — | 10%+ Owner | 2,597,397 | — |
| — | 10%+ Owner | 2,552,189 | — |
| — | 10%+ Owner | 2,276,222 | — |
| — | 10%+ Owner | 2,149,916 | — |
| — | 10%+ Owner | 2,066,935 | — |
| — | 10%+ Owner | 2,054,594 | — |
| — | 10%+ Owner | 2,052,189 | — |
| — | 10%+ Owner | 1,898,851 | — |
| — | 10%+ Owner | 1,883,769 | — |
| — | 10%+ Owner | 1,786,012 | — |
| — | 10%+ Owner | 1,786,012 | — |
| — | 10%+ Owner | 1,786,012 | — |
| — | 10%+ Owner | 1,786,012 | — |
| — | 10%+ Owner | 1,709,967 | — |
| — | Director | 1,162,814 | — |
| — | 10%+ Owner | 1,134,750 | — |
| — | Director | 1,119,256 | — |
| — | Director | 548,726 | — |
| — | Chief Commercial Officer | 370,218 | — |
| — | Chief Medical Officer | 272,862 | — |
| — | Director | 204,803 | — |
| — | President and CEO | 177,455 | — |
| — | Executive Vice President & CFO | 151,387 | — |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the ESPR quote page; the site-wide leaderboard is on the insider transactions hub.